Modality
Nanobody
MOA
SGLT2i
Target
Aβ
Pathway
Neuroinflam
Huntington'sGastric Ca
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
~Jan 2023
→ ~Apr 2024
Phase 2
Jul 2024
→ Apr 2026
Phase 2Current
NCT03510143
2,542 pts·Gastric Ca
2024-07→2026-04·Recruiting
2,542 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-091w awayPh2 Data· Gastric Ca
Trial Timeline
Q3Q42025Q2Q3Q42026Q2
P2
Recruit…
Catalysts
Ph2 Data
2026-04-09 · 1w away
Gastric Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03510143 | Phase 2 | Gastric Ca | Recruiting | 2542 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 |